T. Rowe Price Associates, Inc. (funds and accounts advised by)

Tracked participation in 1 Atlas company, with 0 explicitly attributed leads.

1portfolio companies

2round participations

0lead positions

Sep 2023latest activity

Capital activity

Portfolio

CompanyLatest valuationFirst → latestRoundsRoleAttributed partner

GGenerate:BiomedicinesScienceGenerate:Biomedicines (Nasdaq: GENB) is a clinical-stage therapeutics company focused on “generative biology”: a…$1.1BraisedRecent roundsIPO (initial public offering) · Feb 2026$400M · Cantor Fitzgerald & Co., Goldman Sachs & Co. LLC +3Series C · Sep 2023$273M · Abu Dhabi Investment Authority (ADIA) wholly-owned subsidiary, Abu Dhabi Investment Authority (wholly-owned subsidiary) +10Series B · Nov 2021$370M · Abu Dhabi Investment Authority (ADIA) wholly-owned subsidiary, Abu Dhabi Investment Authority (wholly-owned subsidiary) +8Generate:Biomedicines—Nov 2021 → Sep 20232 roundsParticipant—

DateCompanyRoundRaisedValuationRoleEvidence

Sep 14, 2023GGenerate:BiomedicinesScienceGenerate:Biomedicines (Nasdaq: GENB) is a clinical-stage therapeutics company focused on “generative biology”: a…$1.1BraisedRecent roundsIPO (initial public offering) · Feb 2026$400M · Cantor Fitzgerald & Co., Goldman Sachs & Co. LLC +3Series C · Sep 2023$273M · Abu Dhabi Investment Authority (ADIA) wholly-owned subsidiary, Abu Dhabi Investment Authority (wholly-owned subsidiary) +10Series B · Nov 2021$370M · Abu Dhabi Investment Authority (ADIA) wholly-owned subsidiary, Abu Dhabi Investment Authority (wholly-owned subsidiary) +8Generate:BiomedicinesSeries C$273M—Participant

Source ↗

Nov 18, 2021GGenerate:BiomedicinesScienceGenerate:Biomedicines (Nasdaq: GENB) is a clinical-stage therapeutics company focused on “generative biology”: a…$1.1BraisedRecent roundsIPO (initial public offering) · Feb 2026$400M · Cantor Fitzgerald & Co., Goldman Sachs & Co. LLC +3Series C · Sep 2023$273M · Abu Dhabi Investment Authority (ADIA) wholly-owned subsidiary, Abu Dhabi Investment Authority (wholly-owned subsidiary) +10Series B · Nov 2021$370M · Abu Dhabi Investment Authority (ADIA) wholly-owned subsidiary, Abu Dhabi Investment Authority (wholly-owned subsidiary) +8Generate:BiomedicinesSeries B$370M—Participant

Source ↗

DateCompanyRoundRaisedValuationRoleEvidence

Source ↗